.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 9,101,661

« Back to Dashboard

Details for Patent: 9,101,661

Title:Tamper resistant dosage forms
Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
Inventor(s): McKenna; William H. (Yonkers, NY), Mannion; Richard O. (Furlong, PA), O'Donnell; Edward P. (Basking Ridge, NJ), Huang; Haiyong H. (Princeton, NJ)
Assignee: PURDUE PHARMA L.P. (Stamford, CT) PURDUE PHARMACEUTICALS L.P. (Wilson, NC)
Filing Date:Oct 16, 2014
Application Number:14/515,857
Claims:1. A process of preparing a solid oral extended release pharmaceutical dosage form comprising an extended release matrix comprising a composition, said process comprising the steps of: (a) combining (1) an opioid or a pharmaceutically acceptable salt thereof with each of (2) at least one low molecular weight polyethylene oxide having, based on rheological measurements, an approximate molecular weight of less than 1,000,000, and (3) at least one high molecular weight polyethylene oxide having, based on rheological measurements, an approximate molecular weight of 7,000,000 to form at least one blend; (b) applying each said blend to form a shaped tablet; and (c) curing said shaped tablet by subjecting the shaped tablet to a temperature from about 60 to about 90.degree. C. for a time of from about 15 minutes to about 10 hours, wherein said cured shaped tablet comprises a once-a-day dosage form having at least 79% by weight, based upon the total weight of said composition, of the total combined weight of said high and low molecular weight polyethylene oxides.

2. A process as defined in claim 1, wherein said opioid or pharmaceutically acceptable salt comprises at least 2.4% by weight, based upon the total weight of said composition.

3. A process as defined in claim 2, wherein said curing step comprises one or both of (i) a curing time of 15 minutes to 60 minutes and (ii) a curing temperature of 70 to 78.degree. C.

4. A process as defined in claim 1, wherein said low molecular weight polyethylene oxide comprises a first blend and said high molecular weight polyethylene oxide comprises a second blend, wherein at least one said blend further comprises at least one additive.

5. A process of preparing a solid oral extended release pharmaceutical dosage form comprising an extended release matrix comprising a composition, said process comprising the steps of: (a) combining (1) hydrocodone or a pharmaceutically acceptable salt thereof with each of (2) at least one low molecular weight polyethylene oxide having, based on rheological measurements, an approximate molecular weight of less than 1,000,000 and (3) at least one high molecular weight polyethylene oxide having, based on rheological measurements, an approximate molecular weight of 7,000,000 to form at least one blend; (b) applying each said blend to form a shaped tablet; and (c) curing said shaped tablet by subjecting the shaped tablet to a temperature from about 60 to about 90.degree. C. for a time of from about 15 minutes to about 10 hours, wherein said cured shaped tablet comprises a once-a-day dosage form having at least 79% by weight, based upon the total weight of said composition, of the total combined weight of said high and low molecular weight polyethylene oxides, and wherein said low molecular weight polyethylene oxide comprises at least 20% by weight, based upon the total weight of said composition.

6. A process as defined in claim 5, wherein said curing step comprises one or both of (i) a curing time of 15 minutes to 60 minutes and (ii) a curing temperature of 70 to 78.degree. C.

7. A process as defined in claim 5, wherein said at least one blend further comprises at least one additive.

8. A process as defined in claim 5, wherein said low molecular weight polyethylene oxide is at least 22% by weight and said high molecular weight polyethylene oxide is at least 50% by weight, based upon the total weight of said composition.

9. A process as defined in claim 5, wherein said hydrocodone or pharmaceutically acceptable salt thereof comprises at least 2.4% by weight, based upon the total weight of said composition.

10. A process as defined in claim 5, wherein said hydrocodone or pharmaceutically acceptable salt thereof comprises at least 5% by weight, based upon the total weight of said composition.

11. A process as defined in claim 5, wherein said hydrocodone or pharmaceutically acceptable salt thereof comprises at least 10% by weight, based upon the total weight of said composition.

12. A process as defined in claim 7, wherein said at least one additive is selected from microcrystalline cellulose, hydroxypropyl cellulose, magnesium stearate, and combinations thereof.

13. A process as defined in claim 9, wherein said curing step comprises one or both of (i) a curing time of 15 minutes to 60 minutes and (ii) a curing temperature of 70 to 78.degree. C.

14. A process as defined in claim 5, wherein said low molecular weight polyethylene oxide comprises a first blend and said high molecular weight polyethylene oxide comprises a second blend, wherein at least one said blend further comprises at least one additive.

15. A process as defined in claim 8, wherein said curing step comprises one or both of (i) a curing time of 15 minutes to 60 minutes and (ii) a curing temperature of 70 to 78.degree. C.

16. A process as defined in claim 9, wherein said curing step comprises (i) a curing time of 15 minutes to 60 minutes and (ii) a curing temperature of 70 to 78.degree. C.

17. A process as defined in claim 9, wherein said cured shaped tablet comprises at least 54% high molecular weight polyethylene oxide.

18. A process as defined in claim 5, wherein said cured shaped tablet comprises at least 80% by weight, based upon the total weight of said composition, of said high and low molecular weight polyethylene oxides.

19. A process as defined in claim 5, wherein said cured shaped tablet comprises at least 90% by weight, based upon the total weight of said composition, of said high and low molecular weight polyethylene oxides.

20. A process as defined in claim 9, wherein said cured shaped tablet comprises at least about 80% by weight, based upon the total weight of said composition, of said high and low molecular weight polyethylene oxides.

21. A process as defined in claim 9, wherein said cured shaped tablet comprises at least about 85% by weight, based upon the total weight of said composition, of said high and low molecular weight polyethylene oxides.

22. A process as defined in claim 9, wherein said cured shaped tablet comprises at least about 90% by weight, based upon the total weight of said composition, of said high and low molecular weight polyethylene oxides.

23. A process as defined in claim 1, wherein said curing comprises convection curing in a convection curing device.

24. A process as defined in claim 9, wherein said at least one additive is selected from microcrystalline cellulose, hydroxypropyl cellulose, magnesium stearate, and combinations thereof, and said curing comprises convection curing in a convection curing device.

25. A process as defined in claim 15, wherein said curing comprises convection curing in a convection curing device.

26. A process as defined in claim 25, wherein said curing temperature is measured as a mean exhaust temperature of said convection curing device during said curing time.

27. A process as defined in claim 5 wherein said cured shaped tablet has a density that is at least about 1% lower than the density of said shaped tablet prior to curing.

28. A process as defined in claim 8 wherein said cured shaped tablet has a density that is at least about 1% lower than the density of said shaped tablet prior to curing.

29. A process as defined in claim 26 wherein said cured shaped tablet has a density that is at least about 1% lower than the density of said shaped tablet prior to curing.

30. A process as defined in claim 16, wherein said cured shaped tablet comprises at least 54% high molecular weight polyethylene oxide and has a density that is at least about 1% lower than the density of said shaped tablet prior to curing.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc